Discovery of Zoldonrasib (RMC-9805), a Potent and Orally Bioavailable RAS(ON) G12D-Selective, Covalent, Tri-Complex Inhibitor for the Treatment of Patients with RAS G12D-Addicted Cancers
Burnett, G.L., Weller, C., Jiang, L., Tye, M.A., Tomlinson, A.C.A., Shivakumar, D.M., Xiao, G., Liu, Y., Gliedt, M.J., Edwards, A.V., Aggen, J.B., Lanning, S., Marquez, A., Steele, S.L., Flagella, M., Wang, Z., Singh, M., Wang, Z., Jiang, J., Smith, J.A.M., Wildes, D., Knox, J.E., Koltun, E.S., Gill, A.L.(2026) J Med Chem 


